New analysis indicates that vaccines greatly reduce hospitalisations for flu and COVID-19
A new modelling study from RespiCompass, the ECDC Respiratory Diseases Scenario Modelling Hub, indicates that influenza and COVID-19 vaccination programmes markedly reduced hospitalisations among older adults across Europe in the 2024/25 season.
“Supporting our systems: Addressing immunosenescence and improving adult immunisation in Europe”
The International Longevity Centre UK (ILCUK) report highlights how Europe's aging population faces increasing health challenges due to immunosenescence, which reduces vaccine effectiveness and increases vulnerability to disease.
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis
Two large-scale trials comparing high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) against hospitalisation outcomes have been conducted in Denmark and Spain.
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults
High-dose inactivated influenza vaccine has been shown to provide protection against influenza that is superior to that with the standard dose.
WHO EPI-WIN Webinar: Respiratory Syncytial Virus (RSV) genomic surveillance – how & why
Each year, RSV causes an estimated 3.6 million RSV-associated hospitalisations and approximately 100.000 RSV-attributable deaths in children under 5 years of age worldwide .
Global vaccine confidence trends among adults above and below age 65
This study is interested in global vaccine confidence because it directly impacts vaccination rates and public health outcomes, especially during the COVID-19 pandemic.
Podcast Series: hMPV – A Common Yet Unknown Respiratory Threat
In this 3-part podcast series, the International Federation on Ageing (IFA) aims to raise awareness of hMPV. The series will feature scientists, clinicians and the voices of older people and groups representing those most at risk of serious disease.
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older.